UCB to Acquire Candid for up to $2.2B, Expanding Presence in TCE Antibodies for Immunology
Positive
AI Analysis
Summary
UCB announced a planned acquisition of Candid for up to $2.2B to expand its TCE antibody platform for immunology. The deal reflects UCB's strategy to strengthen its ability to address antibody-mediated autoimmune diseases through multiple approaches.
Outcome Details
Planned acquisition valued at up to $2.2B
Importance:8/10
Sentiment:
0.60
acquisitionimmunologyantibodiesTCE antibodiesautoimmune diseases
Related Companies
Read the original article
Published by GEN - Genetic Engineering & Biotech News on May 6, 2026 12:01 AM